Target intelligence / Profile preview

ATP-dependent protease ATP-binding subunit ClpC2 (ClpC2)

Target
ClpC2
Molecular classification
Enzyme, Chaperone, Transcription factor, AAA+ ATPase family
01

Overview

ClpC2 is a regulatory protein and partial homologue of the essential AAA+ ATPase ClpC1 found in Mycobacterium tuberculosis and other actinobacteria. Unlike ClpC1, which is a core component of the ClpCP protease complex required for protein degradation, ClpC2 lacks the full ATPase motor domains and primarily functions as a transcriptional repressor and a 'molecular sponge.' Under standard growth conditions, ClpC2 represses its own transcription; however, upon exposure to certain natural antibiotics like Cyclomarin A or Rufomycin, the drug binds to ClpC2 and relieves this repression. This leads to a massive upregulation of ClpC2, which then sequesters the antibiotic molecules to prevent them from inhibiting the essential ClpC1 target, thereby protecting the bacterial proteostasis system. This sequestration mechanism represents a significant therapeutic challenge, as it reduces the effective concentration of Clp-targeting drugs. Recent drug development efforts have focused on using BacPROTACs (Bacterial Proteolysis Targeting Chimeras) to induce the simultaneous degradation of both ClpC1 and its ClpC2 caretaker, effectively bypassing this intrinsic resistance mechanism to kill the pathogen.

Other names
ClpC1 partial homologueClp scavenger proteinClpC2 caretakerClpC2 transcriptional repressor
02

Mechanism of action

ClpC2 acts as a molecular sponge by sequestering antibiotics away from the essential ClpC1 target; it also functions as a transcriptional repressor that upregulates itself upon drug binding; BacPROTACs target ClpC2 for degradation to overcome this resistance mechanism.

03

Biological functions

Protein quality controlProteostasisStress responseTranscriptional regulationAntibiotic sequestration
04

Disease associations

Infection
05

Safety considerations

Intrinsic drug resistance due to the molecular sponge effectTherapeutic challenge in achieving sufficient drug concentration to overcome sequestrationPotential for rapid adaptive resistance through transcriptional upregulation
06

Interacting drugs

Cyclomarin A

6 more in the full profile.

07

Biomarkers

ClpC2 protein levelsclpC2 mRNA expression

Beyond the preview

Go deeper on ATP-dependent protease ATP-binding subunit ClpC2 (ClpC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-dependent protease ATP-binding subunit ClpC2 (ClpC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call